4.6 Article

ALDEN, an Algorithm for Assessment of Drug Causality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case-Control Analysis

Journal

CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 88, Issue 1, Pages 60-68

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/clpt.2009.252

Keywords

-

Funding

  1. ADIR Cie
  2. Bayer Pharma/AG/Vital
  3. Boehringer Ingelheim
  4. Cassenne
  5. Ciba-Geigy/Novartis
  6. Cilag GmbH
  7. Willmar Schwabe
  8. Goedecke Parke Davis
  9. Glaxo Wellcome/GlaxoSmithKline
  10. Hoechst AG/Hoechst Marion Roussel/Aventis
  11. Hoffmann-La Roche
  12. IRIS Servier
  13. Jouveinal Lab
  14. LEO
  15. Lilly
  16. MSD Sharp Dohme
  17. Pfizer
  18. Rhone-Poulenc Rorer
  19. Sanofi Winthrop/Sanofi Synthelabo GmbH
  20. Schering AG
  21. INSERM (Institut National de la Sante et de la Recherche Medicale)
  22. French Ministry of Health (PHRC) [AOM 98027, AOM 05092]
  23. Federal Institute for Drugs and Medical Devices (BfArM)

Ask authors/readers for more resources

Epidermal necrolysis (EN)-either Stevens-Johnson syndrome (SJS) or toxic EN (TEN)-is a severe drug reaction. We constructed and evaluated a specific algorithm, algorithm of drug causality for EN (ALDEN), in order to improve the individual assessment of drug causality in EN. ALDEN causality scores were compared with those from the French pharmacovigilance method in 100 cases and the case-control results of the EuroSCAR study. Scores attributed by ALDEN segregated widely. ALDEN pointed to a probable or very probable causality in 69/100 cases as compared to 23/100 with the French method (P < 0.001). It scored very unlikely causality for 64% of medications vs. none with the French method. Results of ALDEN scores were strongly correlated with those of the EuroSCAR case-control analysis for drugs associated with EN (r = 0.90, P < 0.0001), with probable causality being reported in 218/329 exposures. ALDEN excluded causality in 321 drugs that the case-control analysis had described as probably not associated and in 22/233 drugs that had been described as inconclusive exposures. Being more sensitive than a general method, ALDEN, which correlates well with case-control analysis results, can be considered a reference tool in SJS/TEN.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available